Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Completed 2

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 2

Conditions

Colorectal Neoplasms 14Neoplasm Metastasis 5Rectal Neoplasms 3Parkinson Disease 4, Autosomal Dominant Lewy Body 3Stomach Neoplasms 2Gallbladder Neoplasms 2Colonic Neoplasms 2Pancreatic Neoplasms 1Gastrointestinal Neoplasms 1Gastrointestinal Diseases 1Gastric Adenocarcinoma 1Digestive System Diseases 1Cholangiocarcinoma 1Carcinoma 1Bile Duct Neoplasms 1Advanced or Metastatic Solid Tumors 1Advanced Solid Tumors 1Adenocarcinoma 1

Interventions

Oxaliplatin 53Cisplatin 52Fluorouracil 50Capecitabine 48pembrolizumab 38Leucovorin 31Docetaxel 26Trastuzumab 23Paclitaxel 20Irinotecan 20Ramucirumab 12Bevacizumab 12Cetuximab 9Radiotherapy 8Surgical Procedures, Operative 7S 1 (combination) 7Nivolumab 7Epirubicin 7Carboplatin 6olaparib 5Platinum 5Everolimus 5Sunitinib 4Mitomycin 4trastuzumab deruxtecan 3lenvatinib 3epacadostat 3bemarituzumab 3apatinib 3Saline Solution 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Has results × Stomach Neoplasms × trifluridine tipiracil drug combination × Clear all
NCT03686488 2026-03-02

TAS 102 in Combination With Ramucirumab in Advanced, Refractory Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma

H. Lee Moffitt Cancer Center and Research Institute

Phase 2 Completed
23 enrolled 12 charts
Gastrointestinal

Stomach Neoplasms

NCT02500043 2024-09-03

Study of TAS-102 or Placebo Plus BSC in Patients With Metastatic Gastric Cancer

Taiho Oncology, Inc.

Phase 3 Completed
507 enrolled 17 charts 1 FDA
Gastrointestinal

Stomach Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡